Download PDF
Thromb Haemost 1993; 70(06): 1037-1042
DOI: 10.1055/s-0038-1649721
Original Article
Von Willebrand Factor and Endothelial Cells
Schattauer GmbH Stuttgart

The Effect of Interleukin-4 on Tumour Necrosis Factor-Alpha Induced Expression of Tissue Factor and Plasminogen Activator Inhibitor-1 in Human Umbilical Vein Endothelial Cells

N B Martin
Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK
,
A Jamieson
Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK
,
D P Tuffin
Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK
› Author Affiliations
Further Information

Publication History

Received 12 February 1993

Accepted after revision 04 August 1993

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The pro-inflammatory cytokine tumour necrosis factor-a (TNF-α) is able to alter the haemostatic balance of human umbilical vein endothelial cells (HUVECs) towards that of a procoagulant and anti-fibrinolytic state. Treatment of HUVECs in culture with human recombinant TNF-α (0.5-50 U/ml; 6 h) significantly increased total cell expression of tissue factor (TF) 10-fold from 40 mU/well to 400-500 mU/well. Levels of plasminogen activator inhibitor-1 (PAI-1) antigen secreted from HUVECs also increased up to 2-fold in concentration-dependent fashion following addition of TNF-α (10-100 U/ml; 24 h). TNF-α induced total and cell surface expression of TF on HUVECs was significantly inhibited when the cells were pre-incubated with interleukin-4 (IL-4; p <0.001). This effect was time and concentration dependent. Pretreatment of HUVECs with IL-4 for 4 h had no significant effect, but increasing inhibition of total TF expression occurred after 8 and 16 h pre-incubations. Treatment with IL-4 at 20 and 200 U/ml significantly inhibited cell surface TF responses induced by TNF-α, whereas a low concentration (0.2 U/ml) was without effect. In contrast, the production of PAI-1 from HUVECs stimulated by TNF-α (50 U/ml) was unaffected by the presence and/or prior incubation with 200 U/ml IL-4. Thus, IL-4 may regulate the pro-coagulant but not the antifibrinolytic effects of TNF-α at sites of vascular inflammation.

 

  • References

  • 1 Nemerson Y. Tissue factor and Hemostasis. Blood 1988; 71 (01) 1-8
    PubMedGoogle Scholar
  • 2 Bronza JP. Cellular regulation of tissue factor. Blood Coagulation and Fibrinolysis 1990; 1: 415-426
    CrossrefPubMedGoogle Scholar
  • 3 Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edington TS, Lethan E. coli septic shock is prevented by blocking tissue factor with monoclonal antibodies. Circulatory Shock 1991; 33: 127-134
    PubMedGoogle Scholar
  • 4 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843
    CrossrefPubMedGoogle Scholar
  • 5 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone Jr MA. Interleukon-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-623
    CrossrefPubMedGoogle Scholar
  • 6 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1897
    CrossrefPubMedGoogle Scholar
  • 7 Bevilacqua MP, Pober JS, Majeau GR, Friers W, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the action of interleukin-1. Proc Natl Acad Sci USA 1986; 83: 4533-4537
    CrossrefPubMedGoogle Scholar
  • 8 van HinsberghVWM. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 1988; 18: 307-327
    PubMedGoogle Scholar
  • 9 Schleef RR, Wagner NV, Loskutoff DL. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiology 1988; 134: 269-274
    PubMedGoogle Scholar
  • 10 Levin EG, Santell L. Association of plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 1987; 105 (06) 2543-2549
    CrossrefPubMedGoogle Scholar
  • 11 Bartha K, Wojta J, Wagner OF, Binder BR. Comparison of fibrinolytic activities of human and bovine endothelial cells. Am J Physiol 1988; 254: R885-R890
    PubMedGoogle Scholar
  • 12 Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger-RNA in bovine aortic endothelial cells. Thrombosis Res 1989; 54: 41-52
    CrossrefPubMedGoogle Scholar
  • 13 Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-2599
    CrossrefPubMedGoogle Scholar
  • 14 Kapiotis S, Besemer J, Bevec D, Valant P, Bettelheim P, Lechner K, Speiser W. Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood 1991; 78 (02) 410-415
    CrossrefPubMedGoogle Scholar
  • 15 te VeldeAA, Huijbens RJ, Heije K, de VriesJE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1, TNF-α and IL-6 by human monocytes. Blood 1990; 76 (07) 1392-1397
    PubMedGoogle Scholar
  • 16 Standiford TJ, Strieter RM, Chensue SW, Westwick J, Kasahara K, Kunkel SL. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunology 1990; 145: 1435-1439
    PubMedGoogle Scholar
  • 17 Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arteriosclerosis and Thrombosis 1992; 12: 206-211
    CrossrefPubMedGoogle Scholar
  • 18 Corrigan JJ, Bell BM. Endotoxin-induced intravascular coagulation. Prevention by polymyxin-B sulfate. J Lab Clin Invest 1971; 77: 802-810
    PubMedGoogle Scholar
  • 19 Busso N, Huet S, Nicodeme E, Hiernaux J, Hyafil F. Refractory period phenomenon in the induction of tissue factor expression on endothelial cells. Blood 1991; 78 (08) 2027-2035
    PubMedGoogle Scholar
  • 20 Jaffe EA, Nachmann RL, Becker CG, Minick CR. Culture of human endothelial cells derived from human umbilical veins. Identification by morphological and immunological criteria. J Clin Invest 1973; 52: 2745-2747
    CrossrefPubMedGoogle Scholar
  • 21 Surprenant YM, Zuckerman SH. A novel microtiter plate assay for the quantitation of procoagulant activity on adherent monocytes, macrophages and endothelial cells. Thrombosis Res 1989; 53: 339-346
    CrossrefPubMedGoogle Scholar
  • 22 Kirstein M, Fiers W, Baglioni C. Growth inhibition and cytotoxicity of tumor necrosis factor in L929 cells is enhanced by high cell density and inhibition of mRNA synthesis. J Immunol 1986; 137 (07) 2277-22780
    PubMedGoogle Scholar
  • 23 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
    CrossrefPubMedGoogle Scholar
  • 24 Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989; 73 (04) 968-975
    PubMedGoogle Scholar
  • 25 Carson SD, Bronza JP. The role of tissue factor in the production of thrombin. Blood Coag Fibrinol 1993; 4: 281-292
    CrossrefPubMedGoogle Scholar
  • 26 Abbas AK. Cellular interactions in the immune response: The role of B-lymphocytes and interleukin-4. Am J Pathol 1987; 129 (01) 26-33
    PubMedGoogle Scholar
  • 27 Thornhill MH, Haskard DO. II-4 regulated endothelial cell activation by IL-1, tumor necrosis factor or IFN-g. J Immunology 1990; 145 (03) 865-872
    PubMedGoogle Scholar
  • 28 Paleolog EM, Aluri GR, Feldmann M. Contrasting effects of interferon γ and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor α. Cytokine 1992; 4 (06) 470-478
    CrossrefPubMedGoogle Scholar
  • 29 Herbert JM, Savi P, Laplace MC, Lale A. IL-4 inhibits LPS; IL-1β or TNF-α-induced expression of tissue factor in endothelial cells. Letters 1992; 310 (01) 31-33
    PubMedGoogle Scholar
  • 30 Zoellner H, Wojta J, Gallicchio M, McGrath K, Hamilton JA. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells: Comparison with plasminogen activator inhibitor-1 synthesis. Thromb Haemostas 1993; 69 (02) 135-140
    PubMedGoogle Scholar
  • 31 Hamilton JA, Whitty GA, Last K, Royston AK, Hart PH, Burgess DR. Interleukin-3 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood 1992; 80 (01) 121-125
    PubMedGoogle Scholar
  • 32 Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989; 74 (04) 1222-1225
    PubMedGoogle Scholar
  • 33 Hart PH, Whitty GA, Burgess DR, Croatto M, Hamilton JA. Augmentation of glucocorticoid action on human monocytes by interleukin-4. Lymphokine Res 1990; 9 (02) 147-153
    PubMedGoogle Scholar
  • 34 Klaus GGB. Signal transduction via cytokine receptors. 8thAnnual Symposium on Biotechnology. The cytokine system in health and disease 1992: 4 (abst)
    Google Scholar
  • 35 Crutchley DJ, Solomon DE, Conanan LB. Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependant mechanism. Arteriosclerosis and Thrombosis 1992; 12: 664-670
    CrossrefPubMedGoogle Scholar